ASCO Endorses Cancer Care Ontario's Guideline on Active Surveillance for Prostate Cancer

Share this content:
ASCO endorsed Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer.
ASCO endorsed Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer.

The American Society of Clinical Oncology (ASCO) endorsed Cancer Care Ontario's guideline on Active Surveillance for the Management of Localized Prostate Cancer.1

The guidelines stated that for most patients with low-risk localized prostate cancer, defined as Gleason score ≤ 6, active surveillance should be the recommended disease management strategy. Patients with low-volume, intermediate-risk prostate cancer, defined as Gleason score of 3 + 4 = 7, may be offered active surveillance.

Active surveillance includes testing for prostate-specific antigen levels, digital rectal examinations, and serial prostate biopsies.

Patients with discordant clinical and/or pathological findings may receive ancillary radiologic and genomic tests, although they remain investigational.

Patients with a higher-risk category disease, defined as a Gleason score ≥ 7, or who have significant increased tumor volume on subsequent biopsies, should be given active therapy.

RELATED: Enzalutamide Superior to Bicalutamide in Castration-resistant Prostate Cancer

ASCO's Endorsement Panel determined that the recommendations were clear, thorough, and based on the most relevant scientific evidence, although The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not included in the endorsement.

Reference

  1. Chen RC, Rumble B, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline endorsement [published online ahead of print February 16, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.65.7759.

The American Society of Clinical Oncology (ASCO) endorsed Cancer Care Ontario's guideline on Active Surveillance for the Management of Localized Prostate Cancer.1

 

The guidelines stated that for most patients with low-risk localized prostate cancer, defined as Gleason score ≤ 6, active surveillance should be the recommended disease management strategy. Patients with low-volume, intermediate-risk prostate cancer, defined as Gleason score of 3 + 4 = 7, may be offered active surveillance.

 

Active surveillance includes testing for prostate-specific antigen levels, digital rectal examinations, and serial prostate biopsies.

 

Patients with discordant clinical and/or pathological findings may receive ancillary radiologic and genomic tests, although they remain investigational.

 

Patients with a higher-risk category disease, defined as a Gleason score ≥ 7, or who have significant increased tumor volume on subsequent biopsies, should be given active therapy.

 

ASCO's Endorsement Panel determined that the recommendations were clear, thorough, and based on the most relevant scientific evidence, although The Cancer Care Ontario recommendation regarding 5-alpha reductase inhibitors was not included in the endorsement.

 

 

Reference

 

1. Chen RC, Rumble B, Loblaw DA, et al. Active surveillance for the management of localized prostate cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline endorsement [published online ahead of print February 16, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.65.7759.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters